PROCEPT BioRobotics Corp. (NASDAQ:PRCT) shares are down during Thursday’s premarket session following the company’s recent financial results and updates on its revenue guidance.Performance MetricsIn its fourth quarter of 2025, PROCEPT BioRobotics reported total revenue of $76.4 million, marking a 12% increase compared to the prior year, missing the consensus of $94.14 million. The increase was primarily driven by increased handpiece revenue.U.S. handpiece and consumable revenue was $34.0 million, an increas ...

Financial Data and Key Metrics Changes - Insmed reported a strong performance in 2025, with revenue guidance for BRINSUPRI set at a minimum of $1 billion for 2026, reflecting confidence in market access and early launch performance [9][10] - The company anticipates total revenue in 2026 to be more than double that of 2025, driven by both BRINSUPRI and ARIKAYCE [10][37] - As of the end of 2025, Insmed had approximately $1.4 billion in cash, cash equivalents, and marketable securities, positioning the company well for future investments [40][41] Business Line Data and Key Metrics Changes - BRINSUPRI achieved $144.6 million in net revenue in its first full quarter, exceeding expectations and indicating a strong launch trajectory [12] - ARIKAYCE experienced significant growth, particularly in Japan with a 40% increase compared to 2024, contributing over a quarter of its global revenues [31] - The cost of product revenues for Q4 2025 was $44.2 million, or 16.8% of revenues, reflecting improved gross margin due to BRINSUPRI's contributions [45] Market Data and Key Metrics Changes - The total addressable market for BRINSUPRI in the U.S. is estimated at 500,000 diagnosed patients with non-CF bronchiectasis, with significant potential for expansion as more patients are identified [13][18] - The company is actively working to identify additional patients with undiagnosed bronchiectasis among the 32 million diagnosed with COPD or asthma in the U.S. [17][20] Company Strategy and Development Direction - Insmed aims to expand its leadership in bronchiectasis and NTM, with plans to accelerate the U.S. launch of BRINSUPRI while continuing to grow ARIKAYCE [7][8] - The company is pursuing additional DPP1 inhibitors for respiratory diseases, indicating a strategy to broaden its therapeutic offerings [48] - Insmed is focused on educating physicians about bronchiectasis to enhance patient identification and treatment [18][20] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving cash flow positivity without needing to raise additional capital, although they may seek capital for strategic opportunities [11][43] - The positive early feedback from physicians and patients regarding BRINSUPRI is expected to drive increased prescribing behavior in the coming quarters [23][81] - Management highlighted the importance of market access dynamics, noting that over 90% of targeted patient lives have access to BRINSUPRI reimbursement [25][28] Other Important Information - The company received orphan drug designation for TPIP for the treatment of pulmonary arterial hypertension, which could enhance its market position [32] - Insmed is evaluating several business development opportunities to expand its pipeline and support future growth [11][76] Q&A Session Summary Question: Expansion of BRINSUPRI's Total Addressable Market - Management acknowledged the potential for expanding BRINSUPRI's market by identifying patients with COPD or asthma who may have undiagnosed bronchiectasis [47] Question: Guidance for BRINSUPRI and Patient Behavior - Management provided insights into patient compliance and prescription dynamics, indicating strong metrics that support their revenue guidance [51][52] Question: Trends in Prescription and Business Development - Management confirmed strong initial performance and expressed confidence in the ongoing launch, while also discussing potential business development opportunities [54][57] Question: Depth of Prescribing and Education Efforts - Management noted that many physicians are initially prescribing BRINSUPRI to one patient, with expectations that positive experiences will lead to increased prescribing [78][81] Question: Ex-U.S. Contribution to Revenue Guidance - Management indicated that contributions from ex-U.S. markets for BRINSUPRI in 2026 will be minimal, with a focus on U.S. sales [71][72]

Financial Data and Key Metrics Changes - Insmed reported a strong performance in 2025, with revenue guidance for BRINSUPRI of at least $1 billion in 2026, reflecting confidence in market access and early launch performance [5][6][25] - The company anticipates total revenue in 2026 to be more than double that of 2025, indicating a significant growth trajectory [6][25] - As of the end of 2025, Insmed had approximately $1.4 billion in cash, cash equivalents, and marketable securities, positioning the company well for future investments [29][31] Business Line Data and Key Metrics Changes - BRINSUPRI launched in the U.S. with net revenue of $144.6 million in its first full quarter, exceeding expectations [7][20] - ARIKAYCE showed strong growth, particularly in Japan with a 40% increase compared to 2024, contributing significantly to global revenues [21][25] - The company is pursuing additional DPP1 inhibitors for respiratory diseases, indicating a strategy to expand its product portfolio [35] Market Data and Key Metrics Changes - The total addressable market for BRINSUPRI in the U.S. is estimated at 500,000 diagnosed patients with non-CF bronchiectasis, with significant potential for expansion as more patients are identified [8][10] - The company is actively working to identify additional patients with undiagnosed bronchiectasis among those with COPD and asthma, which could significantly increase the patient base for BRINSUPRI [12][13] Company Strategy and Development Direction - Insmed aims to accelerate the U.S. launch of BRINSUPRI while continuing to grow ARIKAYCE, focusing on expanding its clinical pipeline in respiratory, inflammation, immunology, and neurology [4][5] - The company is committed to pursuing first or best-in-class therapies within its target therapeutic areas, indicating a proactive approach to pipeline development [5][6] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving cash flow positivity without needing to raise additional capital, although they may seek capital for strategic opportunities [6][31] - The positive early feedback from physicians and patients regarding BRINSUPRI is expected to drive further prescribing behavior, enhancing the launch's momentum [17][66] Other Important Information - The gross-to-net guidance for BRINSUPRI in 2026 is expected to be in the mid-20s to low 30s percentage range, reflecting favorable payer contracting dynamics [27][28] - The company is evaluating several business development opportunities to support pipeline expansion and value creation [6][31] Q&A Session Summary Question: Plans to develop other DPP1 inhibitors - Insmed intends to bring other DPP1s forward, including INS1033 for rheumatoid arthritis and inflammatory bowel disease, and is also advancing DPP1s for respiratory conditions [35] Question: Guidance for BRINSUPRI and patient behavior - Management is seeing metrics at or above targets, contributing to confidence in achieving at least $1 billion in revenue for BRINSUPRI [39] Question: Trends in scrip data and interest in business development - Management noted strong initial performance and is open to pursuing first or best-in-class compounds for business development [42][45] Question: Depth of prescribing and physician behavior - Physicians are initially prescribing BRINSUPRI to one or two patients, with expectations that positive experiences will lead to increased prescribing [66] Question: Ex-U.S. contribution to BRINSUPRI guidance - Ex-U.S. contributions for BRINSUPRI in 2026 are expected to be very small, with a focus on U.S. market dynamics [58]

Core Insights - Ceragon Networks Ltd. reported Q4 2025 performance aligned with preliminary expectations, showcasing disciplined execution and a strengthened net cash position of $19.4 million [5] - The company anticipates full-year 2026 revenue guidance of $355 million to $385 million, supported by North American backlog advancement and recoveries in other global regions [5] - Management is focusing on high-ROI opportunities and R&D differentiation to drive conversion and margin expansion, rather than reinventing the business model [5] Strategic Execution and Regional Performance Drivers - North American growth is sustained by strong Communication Service Provider (CSP) activity and a growing pipeline of private network opportunities [5] - Operations in India have stabilized, with early 2026 bookings reinforcing confidence in a $100 million annualized revenue baseline [5] - The private network strategy is transitioning from pipeline to revenue, highlighted by a multimillion-dollar turnkey utility win in the APAC region [5] 2026 Guidance Framework and Strategic Initiatives - Anticipated non-GAAP gross margin improvement of approximately 1 percentage point due to a favorable revenue mix and cost-reduction initiatives [5] - Four new products are planned for launch in 2026, with several expected to contribute to revenue within the current fiscal year [5] - Operating margin targets are set at 6.5% to 7.5% at the revenue midpoint, considering current currency assumptions and planned mitigation of component price spikes [5] Operational Risks and Structural Adjustments - Management is addressing a market-wide spike in memory component prices through secondary sourcing and minor product design adjustments [5] - Significant balance sheet improvement achieved through a $49.9 million reduction in trade receivables, primarily from focused collection efforts in India [5] - Currency fluctuations are monitored as a risk, with management estimating that every 1% change in exchange rates impacts annual operating margins by 0.1% [6]

Core Insights - Myriad Genetics reported third-quarter revenue of $205.7 million, slightly above analyst estimates of $204.8 million, but experienced a 3.6% year-on-year decline [6] - Adjusted EPS was $0, beating analyst expectations of -$0.01, while adjusted EBITDA reached $10.3 million, significantly exceeding estimates of $5.57 million [6] - The company reaffirmed its full-year revenue guidance at $823 million and EBITDA guidance at $30 million, above analyst estimates of $27.52 million [6] Revenue and Profitability - The average revenue per test faced ongoing challenges, impacting overall market sentiment negatively despite meeting revenue expectations [1] - Operating margin decreased to -11.3%, down from -9.4% in the same quarter last year, indicating operational headwinds [6] Segment Performance - Strong volume growth was noted in the oncology segment, particularly for the MyRisk hereditary cancer test, which management views as a positive development [1] - The company faced pressures from reduced coverage for the GeneSight mental health test and a divested European business, but core test volumes showed signs of stabilization [1] Analyst Insights - Analysts raised questions regarding the balance between commercial investment and profitability, with management emphasizing an organizational redesign to support growth in cancer care while focusing on profit improvement [6] - Concerns were raised about the prenatal market share and operational improvements, with management addressing customer losses and future growth expectations from FirstGene [6] - Questions regarding hereditary cancer testing volume growth were clarified as stemming from improved customer workflows and EMR integration rather than a temporary rebound [6] Pricing and Market Dynamics - Average selling price declines in hereditary cancer tests were attributed to payer mix, biopharma revenue lumpiness, and changes in UnitedHealthcare's policy [6] - Plans to track an expanded provider base and multi-product adoption were highlighted as future key performance indicators [6] Operational Efficiency - Competitive turnaround times for Prequel and FirstGene tests were confirmed, with expectations for FirstGene to align with Prequel at launch [6]

Group 1 - The article emphasizes the importance of enabling Javascript and cookies in browsers to prevent access issues [1] - It highlights that users with ad-blockers may face restrictions when trying to access content [1]

Revenue Guidance - Topgolf raised its full-year revenue guidance [1] Industry Trend - Football fans spent extra time playing golf [1]

Group 1 - The article does not provide any relevant content regarding company or industry insights [1]

Core Insights - Matrix Service Company reported improved first-quarter results for fiscal 2026, driven by disciplined execution across its Storage & Terminal Solutions and Utility & Power Infrastructure segments [2][4] - The company has a robust opportunity pipeline of $6.7 billion and secured over $187 million in new awards during the quarter, indicating strong demand in the specialty engineering and construction sector [3][9] - The company reaffirmed its full-year revenue guidance, expecting revenue between $875 million and $925 million, representing a 14% to 20% increase compared to fiscal 2025 [19][20] Financial Summary - First-quarter fiscal 2026 revenue was $211.9 million, a 28% increase from $165.6 million in the same period of fiscal 2025 [5][9] - Gross margin improved to $14.2 million (6.7%) compared to $7.8 million (4.7%) in the prior year, attributed to better project execution and increased revenue volumes [6][9] - The company reported a net loss of $3.7 million ($0.13 per share), an improvement from a net loss of $9.2 million ($0.33 per share) in the first quarter of fiscal 2025 [8][9] Segment Performance - The Storage and Terminal Solutions segment saw revenue increase by 40% to $109.5 million, driven by higher work volumes for LNG storage and specialty vessel projects [10] - The Utility and Power Infrastructure segment's revenue rose by 33% to $74.5 million, benefiting from increased work in power delivery and natural gas projects [11] - The Process and Industrial Facilities segment experienced a revenue decline to $27.9 million, primarily due to lower volumes in thermal vacuum chamber projects [12] Backlog and Awards - The total backlog as of September 30, 2025, was $1.2 billion, with project awards totaling $187.8 million for the quarter, resulting in a book-to-bill ratio of 0.9x [13][9] - The Storage and Terminal Solutions segment had a book-to-bill ratio of 1.2x, indicating strong demand and project activity [13][9] Financial Position - As of September 30, 2025, the company had total liquidity of $248.9 million, with no outstanding debt [15][9] - The company reported a total of $192.3 million in unrestricted cash and cash equivalents [15] Guidance - The company reaffirmed its revenue guidance for fiscal year 2026, expecting revenue between $875 million and $925 million, reflecting a significant increase from the previous fiscal year [19][20]

Core Insights - Gentex Corporation's third-quarter 2025 adjusted earnings per share (EPS) of 46 cents missed the Zacks Consensus Estimate of 47 cents and decreased by 13.2% year over year [1][10] - The company reported net sales of $655.2 million, which lagged behind the Zacks Consensus Estimate of $674 million but represented an 8% increase from the previous year [2][10] Financial Performance - Gentex's gross margin improved to 34.4%, an increase of 90 basis points from the third quarter of 2024, attributed to reduced purchasing costs, improved product mix, and operational efficiencies [2] - Total operating expenses rose by 31.3% year over year to $102.84 million, with engineering and R&D expenses increasing to $52.63 million and SG&A expenses rising to $49.69 million [5] Segmental Performance - The Automotive segment's net sales totaled $558 million, down from $596.5 million in the year-ago quarter and below the estimate of $587.5 million, with total shipments declining by 8% to 11,246,000 units [3] - Other net sales, including dimmable aircraft windows and fire protection products, increased slightly from $12 million to $12.5 million [4] Shareholder Returns - Gentex paid a dividend of 12 cents per share and repurchased 1 million shares at an average price of $28.18 per share, with nearly 39.6 million shares authorized for repurchase as of September 30, 2025 [6] Guidance Update - The company revised its 2025 revenue guidance to a range of $2.5-$2.6 billion, up from the previous guidance of $2.44-$2.61 billion, reflecting the impact of the VOXX merger [7] - Sales from the primary market are now expected to be between $2.14-$2.15 billion, and sales from China are projected to be between $135-$145 million, an increase from earlier estimates [7][8]